CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of chronic pain
3.4.1.2. Increase in prevalence of constipation.
3.4.1.3. Rise in availability of effective drugs for constipation treatment
3.4.2. Restraints
3.4.2.1. Side effects associated with drugs.
3.4.2.2. Substitutional options available for idiopathic constipation.
3.4.3. Opportunities
3.4.3.1. Rise in number of adoptions of key strategies by market.
CHAPTER 4: CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Mu-Opioid Receptor Antagonists
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Laxative
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Chloride Channel-2 Activator
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Guanylate Cyclase-C (GC-C) Agonist
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Opioid-Induced Constipation
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Chronic Idiopathic Constipation
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Irritable Bowel Syndrome with Constipation
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE
6.1. Overview
6.1.1. Market size and forecast
6.2. Prescribed Drugs
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Over-the-Counter Drugs
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Online Pharmacy
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Drug Store and Retail Pharmacy
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Others
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: CONSTIPATION TREATMENT MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Product Type
8.2.3. Market size and forecast, by Disease Type
8.2.4. Market size and forecast, by Prescription Type
8.2.5. Market size and forecast, by Distribution Channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Product Type
8.2.6.1.2. Market size and forecast, by Disease Type
8.2.6.1.3. Market size and forecast, by Prescription Type
8.2.6.1.4. Market size and forecast, by Distribution Channel
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Product Type
8.2.6.2.2. Market size and forecast, by Disease Type
8.2.6.2.3. Market size and forecast, by Prescription Type
8.2.6.2.4. Market size and forecast, by Distribution Channel
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Product Type
8.2.6.3.2. Market size and forecast, by Disease Type
8.2.6.3.3. Market size and forecast, by Prescription Type
8.2.6.3.4. Market size and forecast, by Distribution Channel
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Product Type
8.3.3. Market size and forecast, by Disease Type
8.3.4. Market size and forecast, by Prescription Type
8.3.5. Market size and forecast, by Distribution Channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Product Type
8.3.6.1.2. Market size and forecast, by Disease Type
8.3.6.1.3. Market size and forecast, by Prescription Type
8.3.6.1.4. Market size and forecast, by Distribution Channel
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Product Type
8.3.6.2.2. Market size and forecast, by Disease Type
8.3.6.2.3. Market size and forecast, by Prescription Type
8.3.6.2.4. Market size and forecast, by Distribution Channel
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Product Type
8.3.6.3.2. Market size and forecast, by Disease Type
8.3.6.3.3. Market size and forecast, by Prescription Type
8.3.6.3.4. Market size and forecast, by Distribution Channel
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Product Type
8.3.6.4.2. Market size and forecast, by Disease Type
8.3.6.4.3. Market size and forecast, by Prescription Type
8.3.6.4.4. Market size and forecast, by Distribution Channel
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Product Type
8.3.6.5.2. Market size and forecast, by Disease Type
8.3.6.5.3. Market size and forecast, by Prescription Type
8.3.6.5.4. Market size and forecast, by Distribution Channel
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Product Type
8.3.6.6.2. Market size and forecast, by Disease Type
8.3.6.6.3. Market size and forecast, by Prescription Type
8.3.6.6.4. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Product Type
8.4.3. Market size and forecast, by Disease Type
8.4.4. Market size and forecast, by Prescription Type
8.4.5. Market size and forecast, by Distribution Channel
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Product Type
8.4.6.1.2. Market size and forecast, by Disease Type
8.4.6.1.3. Market size and forecast, by Prescription Type
8.4.6.1.4. Market size and forecast, by Distribution Channel
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Product Type
8.4.6.2.2. Market size and forecast, by Disease Type
8.4.6.2.3. Market size and forecast, by Prescription Type
8.4.6.2.4. Market size and forecast, by Distribution Channel
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Product Type
8.4.6.3.2. Market size and forecast, by Disease Type
8.4.6.3.3. Market size and forecast, by Prescription Type
8.4.6.3.4. Market size and forecast, by Distribution Channel
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Product Type
8.4.6.4.2. Market size and forecast, by Disease Type
8.4.6.4.3. Market size and forecast, by Prescription Type
8.4.6.4.4. Market size and forecast, by Distribution Channel
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Product Type
8.4.6.5.2. Market size and forecast, by Disease Type
8.4.6.5.3. Market size and forecast, by Prescription Type
8.4.6.5.4. Market size and forecast, by Distribution Channel
8.4.6.6. Rest of Europe
8.4.6.6.1. Market size and forecast, by Product Type
8.4.6.6.2. Market size and forecast, by Disease Type
8.4.6.6.3. Market size and forecast, by Prescription Type
8.4.6.6.4. Market size and forecast, by Distribution Channel
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Product Type
8.5.3. Market size and forecast, by Disease Type
8.5.4. Market size and forecast, by Prescription Type
8.5.5. Market size and forecast, by Distribution Channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Product Type
8.5.6.1.2. Market size and forecast, by Disease Type
8.5.6.1.3. Market size and forecast, by Prescription Type
8.5.6.1.4. Market size and forecast, by Distribution Channel
8.5.6.2. South Africa,
8.5.6.2.1. Market size and forecast, by Product Type
8.5.6.2.2. Market size and forecast, by Disease Type
8.5.6.2.3. Market size and forecast, by Prescription Type
8.5.6.2.4. Market size and forecast, by Distribution Channel
8.5.6.3. Saudi Arabia
8.5.6.3.1. Market size and forecast, by Product Type
8.5.6.3.2. Market size and forecast, by Disease Type
8.5.6.3.3. Market size and forecast, by Prescription Type
8.5.6.3.4. Market size and forecast, by Distribution Channel
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Product Type
8.5.6.4.2. Market size and forecast, by Disease Type
8.5.6.4.3. Market size and forecast, by Prescription Type
8.5.6.4.4. Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Takeda Pharmaceutical Company Ltd.
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. AbbVie Inc.
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Abbott Laboratories
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. Sanofi S.A.
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Bausch Health Companies Inc.
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Bayer AG
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. AstraZeneca plc
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.8. Ironwood Pharmaceuticals, Inc.
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Prestige Consumer Healthcare Inc.
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Ardelyx Inc.
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Key strategic moves and developments
TABLE 01. GLOBAL CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. CONSTIPATION TREATMENT MARKET FOR MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. CONSTIPATION TREATMENT MARKET FOR LAXATIVE, BY REGION, 2022-2032 ($MILLION)
TABLE 04. CONSTIPATION TREATMENT MARKET FOR CHLORIDE CHANNEL-2 ACTIVATOR, BY REGION, 2022-2032 ($MILLION)
TABLE 05. CONSTIPATION TREATMENT MARKET FOR GUANYLATE CYCLASE-C (GC-C) AGONIST, BY REGION, 2022-2032 ($MILLION)
TABLE 06. CONSTIPATION TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 08. CONSTIPATION TREATMENT MARKET FOR OPIOID-INDUCED CONSTIPATION, BY REGION, 2022-2032 ($MILLION)
TABLE 09. CONSTIPATION TREATMENT MARKET FOR CHRONIC IDIOPATHIC CONSTIPATION, BY REGION, 2022-2032 ($MILLION)
TABLE 10. CONSTIPATION TREATMENT MARKET FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 12. CONSTIPATION TREATMENT MARKET FOR PRESCRIBED DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. CONSTIPATION TREATMENT MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GLOBAL CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 15. CONSTIPATION TREATMENT MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 16. CONSTIPATION TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 17. CONSTIPATION TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. CONSTIPATION TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 24. U.S. CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 25. U.S. CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 26. U.S. CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 27. U.S. CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. CANADA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 29. CANADA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 30. CANADA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 31. CANADA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. MEXICO CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 33. MEXICO CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 34. MEXICO CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 35. MEXICO CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. EUROPE CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 37. EUROPE CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 38. EUROPE CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 39. EUROPE CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. EUROPE CONSTIPATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 41. GERMANY CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 42. GERMANY CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 43. GERMANY CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 44. GERMANY CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. FRANCE CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 46. FRANCE CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 47. FRANCE CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 48. FRANCE CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. UK CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 50. UK CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 51. UK CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 52. UK CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. ITALY CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 54. ITALY CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 55. ITALY CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 56. ITALY CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. SPAIN CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 58. SPAIN CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 59. SPAIN CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 60. SPAIN CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 62. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 63. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 67. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 70. JAPAN CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 71. JAPAN CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 72. JAPAN CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 73. JAPAN CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. CHINA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 75. CHINA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 76. CHINA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 77. CHINA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. INDIA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 79. INDIA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 80. INDIA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 81. INDIA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. AUSTRALIA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 83. AUSTRALIA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 84. AUSTRALIA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 85. AUSTRALIA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. SOUTH KOREA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 87. SOUTH KOREA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 88. SOUTH KOREA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 90. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 91. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 92. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 93. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 94. LAMEA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 95. LAMEA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 96. LAMEA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 97. LAMEA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 98. LAMEA CONSTIPATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 99. BRAZIL CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 100. BRAZIL CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 101. BRAZIL CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 102. BRAZIL CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 103. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 104. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 105. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 106. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 107. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 108. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 109. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 110. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 111. REST OF LAMEA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 112. REST OF LAMEA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 113. REST OF LAMEA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 114. REST OF LAMEA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 115. TAKEDA PHARMACEUTICAL COMPANY LTD.: KEY EXECUTIVES
TABLE 116. TAKEDA PHARMACEUTICAL COMPANY LTD.: COMPANY SNAPSHOT
TABLE 117. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT SEGMENTS
TABLE 118. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT PORTFOLIO
TABLE 119. ABBVIE INC.: KEY EXECUTIVES
TABLE 120. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 121. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 122. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 123. ABBVIE INC.: KEY STRATERGIES
TABLE 124. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 125. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 126. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 127. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 128. SANOFI S.A.: KEY EXECUTIVES
TABLE 129. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 130. SANOFI S.A.: PRODUCT SEGMENTS
TABLE 131. SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 132. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
TABLE 133. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 134. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS
TABLE 135. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 136. BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
TABLE 137. BAYER AG: KEY EXECUTIVES
TABLE 138. BAYER AG: COMPANY SNAPSHOT
TABLE 139. BAYER AG: PRODUCT SEGMENTS
TABLE 140. BAYER AG: PRODUCT PORTFOLIO
TABLE 141. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 142. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 143. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 144. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 145. IRONWOOD PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 146. IRONWOOD PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 147. IRONWOOD PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 148. IRONWOOD PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 149. IRONWOOD PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 150. PRESTIGE CONSUMER HEALTHCARE INC.: KEY EXECUTIVES
TABLE 151. PRESTIGE CONSUMER HEALTHCARE INC.: COMPANY SNAPSHOT
TABLE 152. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT SEGMENTS
TABLE 153. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT PORTFOLIO
TABLE 154. ARDELYX INC.: KEY EXECUTIVES
TABLE 155. ARDELYX INC.: COMPANY SNAPSHOT
TABLE 156. ARDELYX INC.: PRODUCT SEGMENTS
TABLE 157. ARDELYX INC.: PRODUCT PORTFOLIO
TABLE 158. ARDELYX INC.: KEY STRATERGIES
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
